Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313308037> ?p ?o ?g. }
- W4313308037 abstract "Inflammatory breast cancer (IBC), the most aggressive breast cancer subtype, is driven by an immunosuppressive tumor microenvironment (TME). Current treatments for IBC have limited efficacy. In a clinical trial (NCT01036087), an anti-EGFR antibody combined with neoadjuvant chemotherapy produced the highest pathological complete response rate ever reported in patients with IBC having triple-negative receptor status. We determined the molecular and immunological mechanisms behind this superior clinical outcome. Using novel humanized IBC mouse models, we discovered that EGFR-targeted therapy remodels the IBC TME by increasing cytotoxic T cells and reducing immunosuppressive regulatory T cells and M2 macrophages. These changes were due to diminishing immunosuppressive chemokine expression regulated by transcription factor EGR1. We also showed that induction of an immunoactive IBC TME by an anti-EGFR antibody improved the antitumor efficacy of an anti-PD-L1 antibody. Our findings lay the foundation for clinical trials evaluating EGFR-targeted therapy combined with immune checkpoint inhibitors in patients with cancer." @default.
- W4313308037 created "2023-01-06" @default.
- W4313308037 creator A5003469635 @default.
- W4313308037 creator A5008665039 @default.
- W4313308037 creator A5010359709 @default.
- W4313308037 creator A5013941498 @default.
- W4313308037 creator A5018077403 @default.
- W4313308037 creator A5018426062 @default.
- W4313308037 creator A5023674071 @default.
- W4313308037 creator A5025520167 @default.
- W4313308037 creator A5027015803 @default.
- W4313308037 creator A5027464426 @default.
- W4313308037 creator A5028283780 @default.
- W4313308037 creator A5040423978 @default.
- W4313308037 creator A5050866789 @default.
- W4313308037 creator A5057728335 @default.
- W4313308037 creator A5063693068 @default.
- W4313308037 creator A5069614323 @default.
- W4313308037 creator A5077415804 @default.
- W4313308037 creator A5077756892 @default.
- W4313308037 creator A5082739478 @default.
- W4313308037 creator A5084660376 @default.
- W4313308037 creator A5088814426 @default.
- W4313308037 creator A5090187783 @default.
- W4313308037 creator A5091721810 @default.
- W4313308037 creator A5091871767 @default.
- W4313308037 date "2022-12-16" @default.
- W4313308037 modified "2023-10-01" @default.
- W4313308037 title "EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer" @default.
- W4313308037 cites W1484816825 @default.
- W4313308037 cites W1491126364 @default.
- W4313308037 cites W1839411228 @default.
- W4313308037 cites W1919378623 @default.
- W4313308037 cites W1970421873 @default.
- W4313308037 cites W1978346387 @default.
- W4313308037 cites W1980023088 @default.
- W4313308037 cites W1993340690 @default.
- W4313308037 cites W1994710883 @default.
- W4313308037 cites W1997944395 @default.
- W4313308037 cites W2013177587 @default.
- W4313308037 cites W2014208459 @default.
- W4313308037 cites W2024123171 @default.
- W4313308037 cites W2026878412 @default.
- W4313308037 cites W2041515126 @default.
- W4313308037 cites W2048083523 @default.
- W4313308037 cites W2053124553 @default.
- W4313308037 cites W2070875994 @default.
- W4313308037 cites W2097699549 @default.
- W4313308037 cites W2103433909 @default.
- W4313308037 cites W2103964110 @default.
- W4313308037 cites W2104966044 @default.
- W4313308037 cites W2107665951 @default.
- W4313308037 cites W2112121482 @default.
- W4313308037 cites W2112925135 @default.
- W4313308037 cites W2113137803 @default.
- W4313308037 cites W2113334910 @default.
- W4313308037 cites W2116171543 @default.
- W4313308037 cites W2119097383 @default.
- W4313308037 cites W2121592402 @default.
- W4313308037 cites W2123363005 @default.
- W4313308037 cites W2126503106 @default.
- W4313308037 cites W2126865198 @default.
- W4313308037 cites W2128035403 @default.
- W4313308037 cites W2129102832 @default.
- W4313308037 cites W2134539328 @default.
- W4313308037 cites W2135437310 @default.
- W4313308037 cites W2137922932 @default.
- W4313308037 cites W2138095640 @default.
- W4313308037 cites W2138326965 @default.
- W4313308037 cites W2140380746 @default.
- W4313308037 cites W2143488876 @default.
- W4313308037 cites W2153893502 @default.
- W4313308037 cites W2155665993 @default.
- W4313308037 cites W2155802897 @default.
- W4313308037 cites W2158038587 @default.
- W4313308037 cites W2159465679 @default.
- W4313308037 cites W2162222767 @default.
- W4313308037 cites W2168760093 @default.
- W4313308037 cites W2170989872 @default.
- W4313308037 cites W2171524684 @default.
- W4313308037 cites W2179438025 @default.
- W4313308037 cites W2214074259 @default.
- W4313308037 cites W2275249553 @default.
- W4313308037 cites W2320651766 @default.
- W4313308037 cites W2332292689 @default.
- W4313308037 cites W2511743252 @default.
- W4313308037 cites W2531786193 @default.
- W4313308037 cites W2560367415 @default.
- W4313308037 cites W2562305489 @default.
- W4313308037 cites W2562766189 @default.
- W4313308037 cites W2572174216 @default.
- W4313308037 cites W2616669149 @default.
- W4313308037 cites W2733958189 @default.
- W4313308037 cites W2746605095 @default.
- W4313308037 cites W2783471328 @default.
- W4313308037 cites W2784251360 @default.
- W4313308037 cites W2787835497 @default.
- W4313308037 cites W2795394906 @default.
- W4313308037 cites W2796582438 @default.
- W4313308037 cites W2806289425 @default.